Sue Desmond-Hellmann joins Pfizer board; Kite Pharma taps ally in push to expand CAR-T
→ Sue Desmond-Hellmann will be joining Pfizer’s board of directors, four months after stepping down as CEO of the Bill and Melinda Gates Foundation. The American pharma giant has attracted a star-studded board, most recently adding Coca-Cola CEO James Quincey and former FDA chief Scott Gottlieb. Desmond-Hellman is no exception, having spent years at the top of Genentech, where she helped pioneer the first targeted cancer drugs, and serving as the first woman chancellor of the University of California, San Francisco before joining the foundation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.